Mark Portnoy - Aug 25, 2022 Form 4 Insider Report for CRYO CELL INTERNATIONAL INC (CCEL)

Role
Co-CEO, Director, 10%+ Owner
Signature
/s/ Mark Portnoy
Stock symbol
CCEL
Transactions as of
Aug 25, 2022
Transactions value $
$373,403
Form type
4
Date filed
8/29/2022, 05:00 PM
Previous filing
Apr 14, 2022
Next filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCEL Common Stock Options Exercise $187K +59.5K +7.8% $3.14 822K Aug 25, 2022 Direct
holding CCEL Common Stock 42.3K Aug 25, 2022 By 401K
holding CCEL Common Stock 71.5K Aug 25, 2022 By Partnership F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCEL Stock Option Options Exercise $187K +59.5K $3.14 0 Aug 25, 2022 Common Stock 59.5K $3.14 Direct
holding CCEL Stock Option 20K Aug 25, 2022 Common Stock 20K $7.92 Direct
holding CCEL Stock Option 22.2K Aug 25, 2022 Common Stock 22.2K $7.53 Direct
holding CCEL Stock Option 20K Aug 25, 2022 Common Stock 20K $7.28 Direct
holding CCEL Stock Option 20K Aug 25, 2022 Common Stock 20K $13.50 Direct F2, F3
holding CCEL Stock Option 100K Aug 25, 2022 Common Stock 100K $12.27 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of Common Stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark L. Portnoy may be deemed the beneficial owner as its general partner.
F2 The stock options are subject to the approval of the 2022 Equity Incentive Plan, which vote is expected to occur at the Company's 2022 Annual Meeting.
F3 One-third of the stock options will vest on December 22, 2022, one-third will vest on December 22, 2023 and one-third on December 22, 2024.
F4 Stock options vest immediately if the price of the Company's stock reaches $25.00 per share during the seven-year option term.